Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib consolidation in EGFR-mutant stage IIIA-IIIB NSCLC
NCT03396185Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- May 2018
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03396185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396185.